nach oben

Clinical Rheumatology

Erschienen in:

01.07.2007 | Case Report

Treatment of early and refractory dermatomyositis with infliximab: a report of two cases

verfasst von: Sylvia Dold, Maria E. Justiniano, Javier Marquez, Luis R. Espinoza

Erschienen in: Clinical Rheumatology | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

The idiopathic inflammatory myopathies embody the largest group of acquired and potentially treatable causes of skeletal muscle weakness. The three major groups of this disorder are polymyositis (PM), dermatomyositis (DM), and inclusion body myositis. Corticosteroids continue to be the mainstay of initial treatment in the majority of cases of PM/DM. The treatment of refractory disease can be challenging despite the utilization of the medications currently available. We report two patients with refractory DM who were treated with infliximab. We describe their presentation, clinical course, treatment, and outcomes.

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 292:344–347, 403–407PubMedCrossRef

Marie I, Hachulla E, Hatran PY et al (2001) Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol 28:2230–2237PubMed

Airio A, Kautiainen H, Hakala M (2006) Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 25:234–239PubMedCrossRef

Choy EH, Isenberg DA (2002) Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford) 41:7–13CrossRef

Agarwal SK, Monach PA, Docken WP, Coblyn JS (2005) Characterization of relapses in adult idiopathic inflammatory myopathies. Clin Rheumatol 24:1–6CrossRef

Takada K, Nagasaka K, Miyasaka N (2005) Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 38:383–392PubMedCrossRef

Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open label study. Arthritis Rheum 52:601–607PubMedCrossRef

Edge JC, Outland JD, Dempsey JR, Callen JP (2006) Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 142:65–69PubMedCrossRef

Oryoji K, Himaji D, Nagafuji K et al (2005) Successful treatment of rapidly progressive interstitial pneumonia with autologous peripheral blood stem cell transplantation in a patient with dermatomyositis. Clin Rheumatol 24:637–640PubMedCrossRef

10.

Korkmaz C, Tamiz C, Cetinbas F, Buyukkidan B (2004) Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumor necrosis factor-alpha. Rheumatology (Oxford) 43:937–938CrossRef

11.

Anandacoomarasamy A, Howe G, Manolios N (2005) Advanced refractory polymyositis responding to infliximab. Rheumatology 44:562–563PubMedCrossRef

12.

Keystone EC (2004) The utility of tumor necrosis factor blockade in orphan diseases. Ann Rheum Dis 63(Suppl 2):ii79–ii83PubMedCrossRef

13.

Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G (2000) Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol 99:585–588PubMedCrossRef

14.

Shimizu T, Tomita Y, Son K, Nishinarita S, Sawada S, Horie T (2000) Elevation of serum soluble tumor necrosis factor receptor in patients with polymyositis and dermatomyositis. Clin Rheumatol 19:352–359PubMedCrossRef

15.

Pachman LM, Liotta-Davis MR, Hong DK et al (2000) TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 43:2368–2377PubMedCrossRef

16.

Hengstman GJD, van den Hoogen FHJ, Barrera P, Netea MG, Pieterse A, van den Pute LBA et al (2003) Successful treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: Preliminary observations. Eur Neurol 50:10–15PubMedCrossRef

17.

Hengstman GJD, van den Hoogen FHJ, van Engelen BGM (2004) Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol 52:61–63PubMedCrossRef

Titel: Treatment of early and refractory dermatomyositis with infliximab: a report of two cases
verfasst von: Sylvia Dold
Maria E. Justiniano
Javier Marquez
Luis R. Espinoza
Publikationsdatum: 01.07.2007
Verlag: Springer-Verlag
Erschienen in: Clinical Rheumatology / Ausgabe 7/2007
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-006-0325-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Treatment of early and refractory dermatomyositis with infliximab: a report of two cases

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2007

Rheumatoid arthritis is linked to Proteus—the evidence

Seronegative arthritis in patient with solitary bone plasmacytoma

Psychological factors and quality of life in arthritis: a population-based study

Endothelial functions are more severely impaired during active disease period in patients with Behcet’s disease

Combination therapy with cyclosporine A and anti-TNF-α agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection

Reliability and validity of the Turkish version short-form McGill pain questionnaire in patients with rheumatoid arthritis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin